Every material Form 8-K Stereotaxis, Inc. has filed with the SEC since July 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Stereotaxis reported second-quarter 2026 revenue of $7.7 million, down from $8.8 million a year earlier, as system revenue fell to $1.5 million from $3.0 million. Net loss widened to $4.5 million from $3.8 million, and the company said recurring revenue is expected to reach about $7 million in the third quarter and $8 million in the fourth, with cash flow profitability expected in the first half of 2027. Cash was $10.5 million with no debt at June 30, 2026, and the company said it completed its Robocath acquisition.
Q2 2026 total revenue was $7.7 million versus $8.8 million in Q2 2025; recurring revenue rose to $6.2 million from $5.8 million.
System revenue was $1.5 million versus $3.0 million, as no robotic system was delivered in the quarter.
Net loss was $4.5 million versus $3.8 million; adjusted net loss, excluding non-cash charges, was $2.0 million versus $1.3 million.
Guidance: recurring revenue of about $7 million in Q3 and $8 million in Q4, with system revenue of about $3 million in each quarter; cash and equivalents were $10.5 million at June 30, 2026.
Stereotaxis completed its acquisition of Robocath, a French medical device company, on July 7, 2026, and filed supplemental risk factors. The filing says the deal will not be accretive and will increase Stereotaxis's operating losses in the near term, and that issuing shares for the earnout could dilute existing stockholders.
Stereotaxis issued 6,269,628 closing shares at the July 7, 2026 closing, including 225,000 shares paid to Robocath's financial advisor.
The Share Sale Agreement allows up to $25 million of earnout consideration, payable in cash, shares, or both, if regulatory and commercial milestones are met.
Stereotaxis registered 13,179,975 possible earnout shares, with a cap of 19.9% of shares outstanding as of July 7, 2026, including the closing shares.
Stereotaxis extended $1.1 million in operating loans to Robocath before closing; the loans were repaid at closing and reduced the upfront stock consideration.
Stereotaxis completed its acquisition of 100% of Robocath, a French surgical robotics company, on July 7, 2026, for approximately $20 million in cash and common stock. The filing says the company issued 1,469,485 common shares, pre-funded warrants for 4,575,143 shares, and 225,000 shares to Robocath's financial advisor, with up to $25.0 million more in possible earnout consideration.
Acquisition closed July 7, 2026; total consideration approximately $20 million in cash and common stock
Issued 1,469,485 common shares and pre-funded warrants to buy 4,575,143 shares, exercisable until July 7, 2031
Issued 225,000 shares to Robocath's financial advisor as partial success fee payment
Earnout could add up to $25.0 million in shares or warrants, subject to targets, market value and adjustments
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Stereotaxis, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →